Acquisition of Melinta - Narrative (Details) - USD ($) $ / shares in Units, $ in Thousands		3 Months Ended
	Aug. 29, 2025	Mar. 31, 2026	Mar. 31, 2025	Dec. 31, 2025
Acquisition of Melinta [Line Items]
Goodwill		$ 30,002		$ 30,002
Acquisition of Melinta
Acquisition of Melinta [Line Items]
Consideration transferred	$ 453,700
Fair value of contingent payments	95,900	$ 95,900
Goodwill	30,000
Price per share (in dollars per share)		$ 0.001
Total Revenue		$ 29,900
Licensing fees and profit sharing costs			$ 600
Stock compensation expense			100
Depreciation and amortization			9,700
Convertible notes payable			100
Proforma adjustments			$ 2,600
Acquisition of Melinta | Candida
Acquisition of Melinta [Line Items]
Fair value of contingent payments		20,000
Acquisition of Melinta | Aspergillus
Acquisition of Melinta [Line Items]
Fair value of contingent payments		2,500
Acquisition of Melinta | Pneumocystis
Acquisition of Melinta [Line Items]
Fair value of contingent payments		2,500
Acquisition of Melinta | Discount Rate
Acquisition of Melinta [Line Items]
Change in fair value of contingent consideration liability		$ 4,200
Acquisition of Melinta | Marketed Product Values
Acquisition of Melinta [Line Items]
Identified intangible assets	248,100
Acquisition of Melinta | In Process Research and Development
Acquisition of Melinta [Line Items]
Identified intangible assets	$ 143,000